麝香保心丸联合川芎嗪治疗慢性肺源性心脏病急性加重期的效果观察

Effect observation of Shexiang Baoxin Pills combined with Ligustrazine in the treatment of acute exacerbation of chronic pulmonary heart disease

目的探讨麝香保心丸联合川芎嗪治疗慢性肺源性心脏病急性加重期的效果。方法选取2016年6月~2017年5月我院收治的100例慢性肺源性心脏病急性加重期患者作为研究对象,根据随机综合序贯法将其分为4组,分别为A、B、C、D组,每组各25例。A组患者给予西医常规综合治疗;B组患者在西医常规综合治疗的基础上,给予麝香保心丸口服,每次2粒,3次/d,连用10 d;C组患者在西医常规综合治疗的基础上,给予川芎嗪120 mg加入250 ml 5%葡萄糖注射液或0.9%氯化钠注射液中静脉滴注,连用10 d;D组患者在西医常规综合治疗的基础上,给予麝香保心丸口服,每次2粒,3次/d,并联合川芎嗪120 mg加入250 ml 5%葡萄糖注射液或0.9%氯化钠注射液中静脉滴注,连用10 d。比较四组患者治疗前后的脑钠肽(BNP)、第一秒用力呼气容积占肺活量比值(FEV1%)、动脉血氧分压(PaO_2)、动脉血二氧化碳分压(Pa CO_2)及治疗总有效率。结果治疗后,A、B、C组患者的BNP水平低于治疗前,差异有统计学意义(P<0.05),D组患者治疗前后的BNP水平比较,差异无统计学意义(P>0.05)。D组患者的BNP水平高于A、B、C组,差异均有统计学意义(P<0.05)。治疗后,四组患者的FEV1%、PaO_2高于治疗前,Pa CO_2低于治疗前,差异均有统计学意义(P<0.05)。治疗后,D组患者的FEV1%、PaO_2高于A、B、C组,PaCO_2低于A、B、C组,差异均有统计学意义(P<0.05)。D组患者的临床治疗总有效率高于A、B、C组,差异均有统计学意义(P<0.05)。结论麝香保心丸联合川芎嗪治疗慢性肺源性心脏病急性加重期疗效显著,能明显改善患者的心肺功能。

Objective To explore the effect of Shexiang Baoxin Pills combined with Ligustrazine in the treatment of acute exacerbation of chronic pulmonary heart disease.Methods From June 2016 to May 2017,100 patients with acute exacerbation of chronic pulmonary heart disease were selected as subjects and randomly divided into four groups（A,B,C and D,respectively） according to the random comprehensive sequential method,each group of 25 cases.Group A was given routine western medicine comprehensive treatment.Group B was given Shexiang Baoxin Pills orally on the basis of routine western medicine comprehensive treatment,2 tablets per time,three times per day,used for 10 days.Group C was treated with Ligustrazine 120 mg added into the 250 ml 5% glucose injection or 0.9% sodium chloride injection intravenous drip for 10 days.Group D was treated with Shexiang Baoxin Pills orally,2 tablets per time,three times per day,and combination with Ligustrazine 120 mg added into the 250 ml 5% glucose injection or 0.9% sodium chloride injection were injected intravenously for 10 days,on the basis of routine Western medicine.The brain natriuretic peptide（BNP）,the first second forced expiratory volume ratio（FEV1%）,arterial blood oxygen partial pressure（PaO_2）,arterial blood carbon dioxide partial pressure（Pa CO_2） and treatment total efficiency before and after treatment were compared with the four groups of patients.Results After treatment,the BNP levels of patients in the A,B,C group were lower than before the treatment,the differences were statistically significant（P〈0.05）,while there was no statistically significant difference of patients in group D before and after treatment with BNP levels（P〈0.05）.The BNP level of group D was higher than that of group A,B and C,and the differences were statistically significant（P〉0.05）.After treatment,the FEV1%and PaO_2 in the four groups were higher than before treatment,and the differences were statistically significant（P〈0.05）.After treatment,the FEV1% and PaO_2 in group D were higher than those in the group A,B and C,and Pa CO_2 was lower than that in the group A, B and C,with statistically significant differences（P〈0.05）.The total effective rate of clinical treatment in group D was higher than that in group A,B and C,and the differences were statistically significant（P〈0.05）.Conclusion Shexiang Baoxin Pills combined with Ligustrazine in the treatment of acute exacerbation of chronic pulmonary heart disease has a significant effect on improving cardiopulmonary function.